---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-007410"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:32:51.227248+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Coherus Q1 2025: LOQTORZI rev $7.3M, net loss $47.4M; UDENYCA divestiture closed

## Summary
- Continuing ops net loss $47.4M ($0.41 diluted); non-GAAP net loss $40.9M ($0.35).
- LOQTORZI net revenue $7.3M, patient demand grew >15% vs Q4 2024.
- UDENYCA divestiture closed April 2025 for upfront $483.4M, total up to $558.4M.
- CHS-114 Phase 1b shows confirmed partial response in PD-1 refractory HNSCC; proof of mechanism.
- Casdozokitug Phase 2 randomized trial in 1L HCC enrolling; data readout expected 1H 2026.

## SEC filing metadata
- accession: 0001558370-25-007410
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837025007410/0001558370-25-007410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837025007410/chrs-20250512x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-007410
- JSON: https://secwatch.observer/filing/0001558370-25-007410.json
- Plain text: https://secwatch.observer/filing/0001558370-25-007410.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.